The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

Compositions and methods for making and using a water soluble melanin, eumelanin, pheomelanin, allomelanin and DHN-melanin pigment produced from a fungus. The water soluble melanin can be used in a radioprotective composition having at least 0.1 to at least 8.0% (wt./vol.) melanin(s), a solvent and optionally a binder(s) and/or an additive(s). The aqueous soluble melanin has uses in medical, aeronautical, industrial, cosmetic and other applications that are disclosed.

Compositions and methods for making and using a water soluble melanin, eumelanin, pheomelanin, allomelanin and DHN-melanin pigment produced from a fungus. The water soluble melanin can be used in a radioprotective composition having at least 0.1 to at least 8.0% (wt./vol.) melanin(s), a solvent and optionally a binder(s) and/or an additive(s). The aqueous soluble melanin has uses in medical, aeronautical, industrial, cosmetic and other applications that are disclosed.

The disclosed subject matter provides for vaccines against coronaviruses comprising one or more fungal cells genetically engineered to secrete an antigen derived from a coronavirus, e.g., SARS-CoV-2, in situ, and methods of use thereof.

The disclosed subject matter provides for vaccines against coronaviruses comprising one or more fungal cells genetically engineered to secrete an antigen derived from a coronavirus, e.g., SARS-CoV-2, in situ, and methods of use thereof.

The present invention provides a pharmaceutical composition for the treatment of obesity and fatty liver disease caused due to a high-fat diet, containing, as an active ingredient, the powder of a fruiting body or a mycelium of hybrid mushroom strain GBN2WP0970 having no side effects and an excellent triglyceride absorption inhibitory effect.

The present invention relates to a composition comprising at least one plant extract containing at least 0.2% safranal, in particular derived from Crocus Sativus, and at least one probiotic bacterium and/or probiotic yeast, and uses thereof.

The present invention relates to a composition comprising at least one plant extract containing at least 0.2% safranal, in particular derived from Crocus Sativus, and at least one probiotic bacterium and/or probiotic yeast, and uses thereof.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.